MM-151 is an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of the epidermal growth factor receptor (EGFR).
The company said MM-151 is Merrimack’s fifth program to enter clinical development.
The trial is intended to evaluate the safety of MM-151 and determine the recommended Phase 2 dose.
The first patient was enrolled at the Indiana University Health Arnett and Horizon Oncology clinical site and four sites are expected to participate in this trial.